Could a vaccine made from your own tumor fight advanced cancer?

NCT ID NCT05807035

Recruiting now Disease control Sponsor: Vaxine Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a personalized vaccine made from a patient's own tumor tissue. The goal is to see if it is safe and can help the immune system recognize and attack advanced solid cancers. About 30 adults with advanced solid tumors who have already tried other treatments will receive the vaccine, either alone or with standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous tumor vaccine (Radvax) with polysaccharide adjuvant
What this could lead to: If it works, this could point toward a personalized treatment that helps control advanced solid cancers by training the immune system to attack the tumor.
What could go wrong: This is a very early Phase 1 trial with only 30 people, so it is primarily testing safety, not effectiveness. The vaccine may not shrink tumors or improve survival, and there is a risk of side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL CANCER (LYMPHOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

ARASMI
RECRUITING

Adelaide, South Australia, 5046, Australia

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.